Avastin knocked back again by NICE for first-line ovarian cancer
This article was originally published in Scrip
Executive Summary
NICE, the UK's health technology appraisal body, has again said it will not recommend Roche's Avastin (bevacizumab), in combination with paclitaxel and carboplatin, in the first-line treatment of women with metastatic (advanced) ovarian cancer, backing draft guidance published last year.